TORRINGTON, Conn., Jan. 16, 2025 /PRNewswire/ — Therap Services, a national leader in HIPAA-compliant electronic documentation solutions for Long-Term Services and Supports (LTSS), Home and Community-Based Services (HCBS), and other human services sectors, is pleased to announce the addition of a “Record Daily Data” link in the Medication Administration Records (MAR) Data dropdown option on the Individual Home Page. This tool offers users a streamlined way to record and access daily medication data.
Our Daily MAR module is designed to enhance efficiency in managing medication administration. It enables users to schedule and document medications, treatments, PRNs, and PRN follow-ups while utilizing advanced capabilities like barcode and QR code scanning. These features help staff save time, ensure accuracy, and minimize the risk of errors.
If MAR is set up for an individual for the current month, users can conveniently access the new Daily MAR through this new link. It provides seamless access to MAR and allows caregivers to manage and document daily medication data in one place.
This update not only optimizes workflows but also empowers care providers with the tools they need to offer attentive, informed, and responsive support. By continually innovating and improving our technologies, we reaffirm our dedication to fostering better outcomes and enriching the lives of individuals receiving care.
For more information on Therap’s comprehensive eSolution for Person-Centered services, please visit
https://www.therapservices.net/products/comprehensive-esolution-for-person-centered-services/
About Therap
Therap’s comprehensive and HIPAA-compliant software is used in human services settings for documentation, communication, reporting, EVV, and billing.
Learn more at www.therapservices.net
Related Links
SOURCE Therap Services
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…